Advertisement

Ads Placeholder
Loading...

Interparfums SA

ITP.PAEURONEXT
Consumer Defensive
Household & Personal Products
23.50
0.20(0.86%)
U.S. Market opens in 62h 27m

ITP.PA News Today: Stay Updated with the Latest Interparfums SA News in Real Time

Find ITP.PA news now at Meyka AI. Stay informed with the latest Interparfums SA stocks updates, including price news, market analysis, and expert insights.

ITP.TO Intertape Polymer TSX pre-market Mar 2026: Oversold bounce at CAD 40.48
📅 21 days ago

ITP.TO Intertape Polymer TSX pre-market Mar 2026: Oversold bounce at CAD 40.48

ITP.TO stock trades CAD 40.48 pre-market; oversold bounce setup with short-term target CAD 44 and 12-month CAD 48

Read more
ITP.TO Intertape Polymer (TSX) C$40.48 intraday Mar 10 2026: watch 50-day support
📅 24 days ago

ITP.TO Intertape Polymer (TSX) C$40.48 intraday Mar 10 2026: watch 50-day support

Intraday oversold bounce on ITP.TO stock at C$40.48 near 50-day; technical setup and Meyka forecast

Read more
Jefferies Maintains Buy on OLPX Olaplex March 2026
📅 30 days ago

Jefferies Maintains Buy on OLPX Olaplex March 2026

Jefferies maintains Buy on Olaplex; price target cut to $16.25, OLPX analyst rating explained and investor implications

Read more
Samsung Shares Hit Record High on Higher AI Memory Price Report
📅 1 month ago

Samsung Shares Hit Record High on Higher AI Memory Price Report

In a strong sign of investor confidence, Samsung Shares reached a new record high recently after reports emerged that the company is negotiating significantly higher prices for its next-generation AI memory chips. The surge reflects growing demand for advanced semiconductor technology driven by the rapid expansion of artificial intelligence infrastructure and data-intensive computing. This latest…

Read more
Argenx Releases H1 2025 Financials and Q2 Business Highlights
📅 8 months ago

Argenx Releases H1 2025 Financials and Q2 Business Highlights

Argenx, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, has published its first-half 2025 financial results and second-quarter business highlights. The company’s robust pipeline development and strategic partnerships continue to shape its position as a biotech leader in rare diseases. Strong Revenue Growth Driven by Vyvgart Franchise…

Read more

ITP.PA News FAQ